- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00135083
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subjects with type 2 diabetes mellitus who have been using a stable combination oral antidiabetic therapy of 2 or 3 agents in different therapeutic classes for on at least 3 months will be enrolled in this study.
Inclusion Criteria:
- Male and female subjects 18 to 79 years of age with a diagnosis of type 2 diabetes mellitus for at least 6 months
Current treatment with a stable dose of 2 oral antidiabetic agents. The oral agents must be in 2 or 3 of the following 3 different classes:
- Sulfonylurea: dosage greater than or equal to, one-half the maximum recommended dosage (eg, glimepiride >/= 4 mg; glipizide, including gastrointestinal therapeutic system [GITS], >/= 10 mg; glyburide >/= 10 mg; Glynase® >/=3 mg). The dosage must have been stable for at least 3 months prior to screening.
- Biguanide: metformin dosage ≥ 1000 mg daily, including Glucophage XR®. The dosage must have been stable for at least 3 months prior to screening.
- Thiazolidinedione (TZD): pioglitazone >/= 15 mg or rosiglitazone >/= 24 mg. The subject must have been using the same thiazolidinedione for at least 6 months,and the dosage must have been stable for at least 3 months prior to screening.
- HbA1c >/= 8.0%
- Fasting C-peptide concentration > 0.27 nmol/L
- Able and willing to perform self-monitoring of blood glucose (SMBG) up to 4 times a day
- Able and willing to adhere to, and be compliant with, the study protocol
- Able to read English or Spanish at the sixth-grade level in order to complete the subject reported outcomes component of the study
- Signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization
Exclusion Criteria:
- Insulin use within the previous year
- History of hypoglycemia unawareness
- Acute or chronic, or history of, metabolic acidosis, including diabetic ketoacidosis
- Impaired renal function as shown by, but not limited to, serum creatinine ≥ 3mg/dL. For subjects taking metformin, serum creatinine >/= 1.5 mg/dL for males, or >/= 1.4 mg/dL for females.
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than 2.5 times the upper limit of normal (ULN)
- Clinically significant peripheral edema if subject is using a TZD
- History of stroke, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, or angina pectoris, within the past 12 months
- History of, or current, congestive heart failure (New York Heart Association [NYHA] III-IV) requiring pharmacologic treatment
- Acute infection
- Any malignancy within the past 5 years, with the exception of adequately treated basal or squamous cell carcinoma or adequately treated cervical carcinoma in situ
- Current substance addiction or alcohol abuse or history of substance or alcohol abuse, within the past 2 years
- Any clinically significant renal disease (other than proteinuria) or hepatic disease
- Pregnant or lactating females
- Dementia or mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
- Impaired dexterity or vision rendering the subject unable to administer injections
- Known hypersensitivity to insulin glargine or insulin glulisine or any of the components of Lantus or Apidra
- Any disease or condition (including abuse of illicit drugs, prescription medications, or alcohol) that, in the opinion of the investigator or sponsor, may interfere with the completion of the study
- Unlikely to comply with the protocol, eg, uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study
- Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, other staff, or relative thereof, directly involved in the conduct of the protocol
- No subject will be allowed to enroll in this study more than once.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Once daily:
|
|
Experimental: 2
Twice daily:
|
|
Experimental: 3
Twice daily:
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To show non-inferiority between treatment groups (insulin glargine plus insulin glulisine administered once a day, twice a day, or 3 times a day) in the change in glycemic control as measured by hemoglobin A1C.
Time Frame: From baseline to study week 24.
|
From baseline to study week 24.
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Karen Barch, B.S., Sanofi
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMR1964A_3511
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on insulin glulisine
-
Profil Institut für Stoffwechselforschung GmbHSanofiCompleted
-
SanofiCompleted
-
SanofiCompletedDiabetes Mellitus, Type 2France, Spain, Italy, Belgium, Germany, Poland, Portugal, Czech Republic, Slovakia, Australia, Netherlands, Sweden, United Kingdom, Switzerland, Romania
-
SanofiTerminated
-
SanofiCompletedDiabetes Mellitus, Type 2Japan
-
SanofiTerminatedDiabetes Mellitus, Type 2Brazil
-
SanofiCompletedDiabetes Mellitus, Type 2United States